Analyst Price Target is $36.00
▲ +110.90% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Viridian Therapeutics in the last 3 months. The average price target is $36.00, with a high forecast of $40.00 and a low forecast of $28.00. The average price target represents a 110.90% upside from the last price of $17.07.
Current Consensus is
The current consensus among 4 polled investment analysts is to buy stock in Viridian Therapeutics.
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma; and remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.